DOI QR코드

DOI QR Code

New Technologies For Health Foods and Nutraceuticals

  • Published : 2002.06.01

Abstract

Keywords

References

  1. Yalpani M. 1997. New Technologies for Healthy Foods & Nutraceuticals. Yalpani M, ed. ATL press, Mount Prospect. p 1-10
  2. Anon. 2000. Nutr Bus J
  3. Challener C. 2000. Specialty dietary supplement ingredients are the hot spot. Chem Market Rep 258 (Sep. 25): pFR8
  4. Anon. 1998. Nutr Bus J
  5. Mettienen TA, Gylling H. 1997. In New Technologies for Healthy Foods & Nutraceuticals. Yalpani M, ed. ATL press, Mount Prospect. p 53-70
  6. Wilhelm C. 2000. Leveling demand for dietary supplements. Chem Market Rep 257 (May 29): pFR8
  7. Jiang Q, Elson-Schwab I, Courtmanche C, Ames BN. 2000. Gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci 10: 11494- 11499
  8. Khor HT, Chieng DY. 1997. Effect of squalene, tocotrienols and tocopherol supplementations in the diet on serum and liver lipids in the hamster. Nutr Res 17: 475-483 https://doi.org/10.1016/S0271-5317(97)00006-7
  9. Goh SH, Hew NF, Norhanom AW, Yadav M. 1997. Inhibition of tumour promotion by various palm-oil tocotrienols. Int J Cancer 57: 529-531
  10. Yalpani M. 1997. In New Technologies for Healthy Foods & Nutraceuticals. Yalpani M, ed. ATL press, Mount Prospect, p 53-70
  11. Gershwin ME, German JB. 2000. Nutr Immunol. Humana Press, Totowa NJ
  12. Riggi SJ, Di Luzzio NR. 1961. Am J Physiol 200: 297
  13. Borchers AT, Stern JS, Hackman RM, Keen CL, Gershwin ME. 1999. Mushrooms, tumors, and immunity. Proc Soc Exp Biol Med 221: 281-293 https://doi.org/10.1046/j.1525-1373.1999.d01-86.x
  14. Hayakawa K, Mitsuhashi N, Saito Y, Takahashi M, Katano S, Shiojima K, Furuta M, Niibe H. 1993. Anticancer Res 13: 174-409
  15. Goldman RC. 1996. Ann Rep Medicinal Chem 30: 129-138
  16. Ink S, Mathews R. 1997. In New Technologies for Healthy Foods & Nutraceuticals. Yalpani M, ed. ATL Press, Mount Prospect. p 195-235
  17. Mizuno M, Minato K, Ito H, Kawade M, Terai H, Tsuchida H. 1999. Biochem Mol Bio Int 47: 707-714
  18. Popvitch B. 2000. Business Communication Co. Chem Market Rep 258 (Sep. 25)
  19. Mascarenhas MR, Tershakovec AM, Stettler N. 1999. Nutrition interventions in childhood for the prevention of chronic disease in adulthood. Curr Opin Pediatr 11: 598-604 https://doi.org/10.1097/00008480-199912000-00023
  20. Luke RB. 2001 (June). Supplements for joint health. Nutraceuticals World
  21. Groop PH. 1997. In New Technologies for Healthy Foods & Nutraceuticals. Yalpani M, ed. ATL Press, Mount Prospect. p 179-194
  22. Khan AR, Khan GY, Mitchell A, Quadeer MA. 1981. Effect of guar gum on blood lipids. Am J Clin Nutr 39: 2446-2449
  23. Wu J, Peng SS. 1997. Comparison of hypolipidemic effect of refined konjac meal with several common dietary fibers and their mechanisms of action. Biomed Environ Sci 10: 27-37
  24. Emako M, Tomohisa T, Katsuyoshi N. 1998. Effects of glucose, mannose and konjac glucomannan on the gel-sol transition in gellan gum aqueous solutions by rheology and DSC. Polym Gels Networks 6: 273-290 https://doi.org/10.1016/S0966-7822(98)00019-7
  25. Levrat-Verny MA, Behr S, Mustad V, Remesy, Demigne C. 2000. Low levels of viscous hydrocolloids lower plas-ma cholesterol in rats primarily by impairing cholesterol absorption. J Nutr 130: 243-248
  26. Braaten JT, Wood PJ, Scott FW, Wolynetz MS, Lowe MK, Bradley-White P, Collins MW.1994. Oat beta-glucan reduces blood cholesterol concentration in hypercholes-terolemic subjects. Eur J Clin Nutr 48: 465-474
  27. Braaten JT, Scott FW, Wood PJ, Riedel KD, Wolynetz MS, Brule D, Collins MW. 1994. High beta-glucan oat bran and oat gum reduce postprandial blood glucose and insulin in subjects with and without type 2 diabetis. Diab Med 11: 312-318 https://doi.org/10.1111/j.1464-5491.1994.tb00277.x
  28. Madar Z, Abel R, Samish S, Arad J. 1988. Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. Eur J Clin Nutr 42: 51-54
  29. Gordon DT, Topp K, Shi YC, Zallie J, Jeffcoat R. 1997. In New Technologies for Healthy Foods & Nutraceuticals. Yalpani M, ed. ATL Press, Mount Prospect. p 157-178
  30. Haralampu SG. 2000. Resistant starch a review of the phys-ical properties and biological impact of RS3. Carbohyd Polym 41: 285-292 https://doi.org/10.1016/S0144-8617(99)00147-2
  31. Ghannam N, Kingston M, Al-Meshaal IA, Tariq M, Parman NS, Woodhouse N. 1986. The antidiabetic activity of aloes preliminary clinical and experimental observations. Hormone Res 24: 288-294 https://doi.org/10.1159/000180569
  32. Morellei V, Zoorob RJ. 2000. Alternative therapies: part 1, depression, diabetes, obesity. Am Family Physician 62: 1051-1060
  33. Parkash A, Ng TB, Tso WW. 2002. Putrification and char-acterization of charantin, a napin-like ribosome-inactivating peptide from bitter gourd (Momordica charantia) seeds. J Peptide Res 59: 197-202
  34. Leatherdale BA, Panesar R, Singh G, Atkins TW, Bailey CJ, Bigwell AH. 1981. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J 282: 1823-24 https://doi.org/10.1136/bmj.282.6279.1823
  35. Welihinda J, Karunanaya E, Sheriff MHB, Jayasinghe K. 1986. J Ethnopharm 17: 277-282 https://doi.org/10.1016/0378-8741(86)90116-9
  36. Chandrasekar B, Mukherjee B, Mukherjee SK. 1989. Indian J Med Res 90: 300-305
  37. Parakash AO, Mathur S, Mathur R. 1986. Effect of feed-ing Gymnema sylvestre leaves on blood glucose in beryl-lium nitrate treated rats. J Ethnopharm 18: 143-146 https://doi.org/10.1016/0378-8741(86)90026-7
  38. Shapiro K, Gong WC. 2002. Natural products used for dia-betes. J Am Pharm Asso 42: 217-226 https://doi.org/10.1331/108658002763508515
  39. Frati-Munari AC, Fernandez-Harp JA, de la Riva H, Ariza- Andraca R, del Carmen Torres M. 1983. Effects of nopal (Opuntia sp.) on serum lipids, glycemia and body weight. Arch Invest Med 14: 117-125
  40. Jarvus L. 2001. Lutein buoys supplements market with eye health applications. Chem Market Rep 260 (July 16): 10
  41. Miki W. 1992. Recent advances in carotenoid studies-metabolisms and bioactivities. J Nutr Sci Vitaminol 38: 469-472 https://doi.org/10.3177/jnsv.38.Special_469
  42. de la Monte SM, Sohn YK, Wands JR. 1997. Correlates of p53- and Fas (CD95) mediated apoptosis in Alzheimers disease. J Neurol Sci 152: 73-83 https://doi.org/10.1016/S0022-510X(97)00131-7
  43. de la Monte SM, Sohn YK, Ganju N, Wands JR. 1998. P53- and CD95-associates apoptosis in neurodegenerative diseases. Lab Invest 78: 401-411 https://doi.org/10.1111/1523-1747.ep12507553
  44. Parkinson Study Group. 1993. N Eng J Med. 328: 176-183 https://doi.org/10.1056/NEJM199301213280305
  45. Kontush A, Mann U, Arlt S, Ujeyl A, Luhrs C, Muller- Tomsen T, Beisiegel U. 2001. Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. Free Radic Biol Med 31: 345-354 https://doi.org/10.1016/S0891-5849(01)00595-0
  46. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E. 2001. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 30: 235-241 https://doi.org/10.1093/ageing/30.3.235
  47. Franchi F. 1998. Arch Geront Geriatrics 6: 207-214
  48. McDowell I. 2001. Alzheimers disease: insights from epidemiology. Aging 13: 143-162
  49. Yalpani M. 2002. US Pat. Application

Cited by

  1. Preparation of High Purity Chondroitin Sulfate vol.10, pp.4, 2009, https://doi.org/10.5762/KAIS.2009.10.4.865
  2. Anti-oxidative Properties of Lipids Extracted from Rainbow Trout (Oncorhynchus mykiss) Fed with Carotenoids and Conjugated Linoleic Acid vol.12, pp.4, 2009, https://doi.org/10.5657/fas.2009.12.4.258